Dr. Andreadis on CAR T-Cell Therapy in Relapsed/Refractory MCL

Video

Charalambos (Babis) Andreadis, MD, MSCE, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma (MCL).

The BTK inhibitors ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa) are active in relapsed/refractory MCL and have shown significant response rates; however, patients continue to relapse on these regimens, explains Andreadis. The median duration of response for BTK inhibitors is 1.5 years. Therefore, new therapies are necessary for this patient population, says Andreadis.

The emergence of CAR T-cell therapy has shown significant benefit in patients with relapsed/refractory MCL who are heavily pretreated. The CAR T-cell therapies lisocabtagene maraleucel (JCAR017) and axicabtagene ciloleucel (Yescarta), according to Andreadis, are showing 70% to 90% response rates and 50% to 60% complete response rates in patients with relapsed/refractory disease. Andreadis believes CAR T-cell therapy will be significant in the future of MCL treatment.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.